These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16140071)

  • 1. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
    Gårdmark T; Carringer M; Beckman E; Malmström PU;
    Urology; 2005 Sep; 66(3):527-30. PubMed ID: 16140071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder.
    Maffezzini M; Campodonico F; Canepa G; Capponi G; Fontana V
    Eur Urol; 2007 Apr; 51(4):956-61. PubMed ID: 17027141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
    Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
    Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.
    Campodonico F; Canepa G; Capponi G; Bozzo L; Maffezzini M
    Anticancer Res; 2005; 25(3c):2381-4. PubMed ID: 16080464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
    Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
    J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder.
    Campodonico F; Maffezzini M
    Urology; 2005 Nov; 66(5):1141-2; author reply 1142. PubMed ID: 16286156
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).
    Gontero P; Casetta G; Maso G; Sogni F; Pretti G; Zitella A; Frea B; Tizzani A
    Eur Urol; 2004 Sep; 46(3):339-43. PubMed ID: 15306105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
    Messing EM; Tangen CM; Lerner SP; Sahasrabudhe DM; Koppie TM; Wood DP; Mack PC; Svatek RS; Evans CP; Hafez KS; Culkin DJ; Brand TC; Karsh LI; Holzbeierlein JM; Wilson SS; Wu G; Plets M; Vogelzang NJ; Thompson IM
    JAMA; 2018 May; 319(18):1880-1888. PubMed ID: 29801011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
    DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
    J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
    Palou J; Carcas A; Segarra J; Duque B; Salvador J; Garcia-Ribas I; Villavicencio H
    J Urol; 2004 Aug; 172(2):485-8. PubMed ID: 15247710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
    Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
    Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.
    Bartoletti R; Cai T; Gacci M; Giubilei G; Viggiani F; Santelli G; Repetti F; Nerozzi S; Ghezzi P; Sisani M;
    Urology; 2005 Oct; 66(4):726-31. PubMed ID: 16230125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
    Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
    J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.
    Gunelli R; Bercovich E; Nanni O; Ballardini M; Frassineti GL; Giovannini N; Fiori M; Pasquini E; Ulivi P; Pappagallo GL; Silvestrini R; Zoli W
    Br J Cancer; 2007 Dec; 97(11):1499-504. PubMed ID: 17987035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical therapy for superficial cancer: need for more options.
    Crawford ED
    J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.
    Dalbagni G; Russo P; Bochner B; Ben-Porat L; Sheinfeld J; Sogani P; Donat MS; Herr HW; Bajorin D
    J Clin Oncol; 2006 Jun; 24(18):2729-34. PubMed ID: 16782913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure.
    Allchorne P; Lamb BW; Kinsella J; Shamash J; Green JS
    Urol Nurs; 2014; 34(2):95-9. PubMed ID: 24919248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.